Santen Pharmaceutical Co Ltd
TSE:4536
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 384.5
1 876.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Santen Pharmaceutical Co Ltd
Operating Margin
Santen Pharmaceutical Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | JP |
| Market Cap | 546.6B JPY |
| Operating Margin |
12%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Operating Margin |
-83%
|
| Country | US |
| Market Cap | 755.8B USD |
| Operating Margin |
35%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Operating Margin |
3%
|
| Country | DK |
| Market Cap | 2.7T DKK |
| Operating Margin |
44%
|
| Country | US |
| Market Cap | 351.1B USD |
| Operating Margin |
28%
|
| Country | US |
| Market Cap | 251.8B USD |
| Operating Margin |
34%
|
| Country | CH |
| Market Cap | 200.1B CHF |
| Operating Margin |
32%
|
| Country | UK |
| Market Cap | 161.8B GBP |
| Operating Margin |
21%
|
| Country | CH |
| Market Cap | 171.5B CHF |
| Operating Margin |
31%
|
| Country | US |
| Market Cap | 151.5B USD |
| Operating Margin |
22%
|
Santen Pharmaceutical Co Ltd
Glance View
Santen Pharmaceutical Co., Ltd., a cornerstone of Japan's robust pharmaceutical industry, has been relentlessly focused on improving eye health worldwide. Founded in 1890, the company began as a modest medicine retailer in Osaka, but over the decades, it has skillfully navigated the evolving healthcare landscape to become a global leader in ophthalmology. Today, Santen's enterprise is intricately woven with innovation and specialization, stretching its influence far beyond its Japanese roots. Its main thrust lies in the research, development, and commercialization of ophthalmic products tackling a comprehensive range of eye disorders, from dry eyes to age-related macular degeneration and glaucoma. By investing significantly in R&D, Santen maintains a robust pipeline of new treatments that continuously feeds into its growing portfolio, ensuring its offerings are at the forefront of medical advancements. Santen's business strategy thrives on leveraging its scientific expertise to not only create but also efficiently bring products to market across various continents. It operates through a well-crafted distribution network that spans Asia, Europe, and North America, tailoring its marketing and regulatory approaches to suit regional healthcare environments. This global footprint allows Santen to capture diverse markets, each with unique demands, thereby enhancing revenue streams. The firm's operational model also includes strategic partnerships and acquisitions, enhancing its research capabilities and expanding its market share to sustain profitability. Santen generates revenue primarily through the sale of innovative ophthalmic prescription drugs and over-the-counter products, supported by its strong relationships with healthcare professionals and continued expansion into emerging markets. The company’s focused strategy and commitment to eye health solutions position it as an indispensable player in the global healthcare industry.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Santen Pharmaceutical Co Ltd's most recent financial statements, the company has Operating Margin of 12.3%.
You don't have any saved screeners yet
